Class information for:
Level 1: SURROGATE ENDPOINT//SURROGATE OUTCOME//PRENTICE CRITERION

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
18139 564 29.6 72%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
9 4 COMPUTER SCIENCE, THEORY & METHODS//COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE//COMPUTER SCIENCE, INFORMATION SYSTEMS 1247339
34 3       STATISTICS & PROBABILITY//STAT//COMMUNICATIONS IN STATISTICS-THEORY AND METHODS 105938
319 2             STATISTICS & PROBABILITY//STATISTICS IN MEDICINE//BIOMETRICS 18302
18139 1                   SURROGATE ENDPOINT//SURROGATE OUTCOME//PRENTICE CRITERION 564

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SURROGATE ENDPOINT authKW 1445453 17% 28% 95
2 SURROGATE OUTCOME authKW 381598 3% 41% 17
3 PRENTICE CRITERION authKW 331603 1% 88% 7
4 POST PROGRESSION SURVIVAL authKW 300766 2% 56% 10
5 PRENTICE CRITERIA authKW 294757 1% 78% 7
6 PROGRESSION FREE SURVIVAL authKW 273230 11% 8% 61
7 LIKELIHOOD REDUCTION FACTOR authKW 270698 1% 100% 5
8 META ANALYTIC APPROACH authKW 270698 1% 100% 5
9 SURROGATE THRESHOLD EFFECT authKW 225580 1% 83% 5
10 PROPORTION EXPLAINED authKW 173245 1% 80% 4

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Statistics & Probability 11438 35% 0% 196
2 Mathematical & Computational Biology 9241 24% 0% 133
3 Medical Informatics 7010 14% 0% 78
4 Oncology 1817 30% 0% 171
5 Medicine, Research & Experimental 951 16% 0% 91
6 Health Care Sciences & Services 646 8% 0% 43
7 Public, Environmental & Occupational Health 443 13% 0% 71
8 Biology 421 8% 0% 47
9 Pharmacology & Pharmacy 341 16% 0% 93
10 Social Sciences, Mathematical Methods 44 1% 0% 7

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 OFF CLIN PHARMACOLGENOM GRP 162419 1% 100% 3
2 BIOMETR 5 157487 1% 36% 8
3 ONCOL THER Y AREA 121812 1% 75% 3
4 BIOSTAT QUAL LIFE UNIT EA4184 108279 0% 100% 2
5 PREDICT SAFETY TESTING CONSORTIUM 108279 0% 100% 2
6 DATA CANC CLIN TRIALS 97449 1% 60% 3
7 METHODOL QUAL LIFE UNIT ONCOL EA3181 72185 0% 67% 2
8 ADOBE INDIA S 54140 0% 100% 1
9 ADULT STAT DATA ANAL 54140 0% 100% 1
10 ANESTHESIOLOGY 54140 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 STATISTICS IN MEDICINE 22010 10% 1% 54
2 BIOMETRICS 18238 7% 1% 39
3 JOURNAL OF BIOPHARMACEUTICAL STATISTICS 15132 3% 2% 16
4 CLINICAL TRIALS 12305 2% 2% 13
5 STATISTICAL METHODS IN MEDICAL RESEARCH 10555 2% 2% 12
6 PHARMACEUTICAL STATISTICS 8335 2% 2% 9
7 STATISTICS IN BIOPHARMACEUTICAL RESEARCH 6378 1% 2% 6
8 BIOMARKERS IN MEDICINE 4999 1% 1% 8
9 DRUG INFORMATION JOURNAL 3980 2% 1% 9
10 THERAPEUTIC INNOVATION & REGULATORY SCIENCE 3719 1% 1% 5

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SURROGATE ENDPOINT 1445453 17% 28% 95 Search SURROGATE+ENDPOINT Search SURROGATE+ENDPOINT
2 SURROGATE OUTCOME 381598 3% 41% 17 Search SURROGATE+OUTCOME Search SURROGATE+OUTCOME
3 PRENTICE CRITERION 331603 1% 88% 7 Search PRENTICE+CRITERION Search PRENTICE+CRITERION
4 POST PROGRESSION SURVIVAL 300766 2% 56% 10 Search POST+PROGRESSION+SURVIVAL Search POST+PROGRESSION+SURVIVAL
5 PRENTICE CRITERIA 294757 1% 78% 7 Search PRENTICE+CRITERIA Search PRENTICE+CRITERIA
6 PROGRESSION FREE SURVIVAL 273230 11% 8% 61 Search PROGRESSION+FREE+SURVIVAL Search PROGRESSION+FREE+SURVIVAL
7 LIKELIHOOD REDUCTION FACTOR 270698 1% 100% 5 Search LIKELIHOOD+REDUCTION+FACTOR Search LIKELIHOOD+REDUCTION+FACTOR
8 META ANALYTIC APPROACH 270698 1% 100% 5 Search META+ANALYTIC+APPROACH Search META+ANALYTIC+APPROACH
9 SURROGATE THRESHOLD EFFECT 225580 1% 83% 5 Search SURROGATE+THRESHOLD+EFFECT Search SURROGATE+THRESHOLD+EFFECT
10 PROPORTION EXPLAINED 173245 1% 80% 4 Search PROPORTION+EXPLAINED Search PROPORTION+EXPLAINED

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 ENSOR, H , LEE, RJ , SUDLOW, C , WEIR, CJ , (2016) STATISTICAL APPROACHES FOR EVALUATING SURROGATE OUTCOMES IN CLINICAL TRIALS: A SYSTEMATIC REVIEW.JOURNAL OF BIOPHARMACEUTICAL STATISTICS. VOL. 26. ISSUE 5. P. 859 -879 74 79% 0
2 SHI, Q , SARGENT, DJ , (2009) META-ANALYSIS FOR THE EVALUATION OF SURROGATE ENDPOINTS IN CANCER CLINICAL TRIALS.INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. VOL. 14. ISSUE 2. P. 102 -111 53 76% 26
3 CIANI, O , CANTRELL, A , DAVIS, S , TAPPENDEN, P , SAAD, ED , GARSIDE, R , BUYSE, M , STEIN, K , TAYLOR, RS , (2014) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS.INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. VOL. 30. ISSUE 3. P. 312 -324 40 74% 7
4 BUYSE, M , MOLENBERGHS, G , PAOLETTI, X , OBA, K , ALONSO, A , VAN DER ELST, W , BURZYKOWSKI, T , (2016) STATISTICAL EVALUATION OF SURROGATE ENDPOINTS WITH EXAMPLES FROM CANCER CLINICAL TRIALS.BIOMETRICAL JOURNAL. VOL. 58. ISSUE 1. P. 104 -132 35 59% 5
5 LASSERE, MN , (2008) THE BIOMARKER-SURROGACY EVALUATION SCHEMA: A REVIEW OF THE BIOMARKER-SURROGATE LITERATURE AND A PROPOSAL FOR A CRITERION-BASED, QUANTITATIVE, MULTIDIMENSIONAL HIERARCHICAL LEVELS OF EVIDENCE SCHEMA FOR EVALUATING THE STATUS OF BIOMARKERS AS SURROGATE ENDPOINTS.STATISTICAL METHODS IN MEDICAL RESEARCH. VOL. 17. ISSUE 3. P. 303 -340 47 57% 55
6 RENFRO, LA , SHI, Q , XUE, Y , LI, J , SHANG, H , SARGENT, DJ , (2014) CENTER-WITHIN-TRIAL VERSUS TRIAL-LEVEL EVALUATION OF SURROGATE ENDPOINTS.COMPUTATIONAL STATISTICS & DATA ANALYSIS. VOL. 78. ISSUE . P. 1 -20 25 96% 2
7 PRASAD, V , KIM, C , BUROTTO, M , VANDROSS, A , (2015) THE STRENGTH OF ASSOCIATION BETWEEN SURROGATE END POINTS AND SURVIVAL IN ONCOLOGY A SYSTEMATIC REVIEW OF TRIAL-LEVEL META-ANALYSES.JAMA INTERNAL MEDICINE. VOL. 175. ISSUE 8. P. 1389 -1398 37 47% 21
8 SHERRILL, B , KAYE, JA , SANDIN, R , CAPPELLERI, JC , CHEN, C , (2012) REVIEW OF META-ANALYSES EVALUATING SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ONCOLOGY.ONCOTARGETS AND THERAPY. VOL. 5. ISSUE . P. 287-296 30 63% 17
9 CIANI, O , BUYSE, M , GARSIDE, R , PETERS, J , SAAD, ED , STEIN, K , TAYLOR, RS , (2015) META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS SHOW SUBOPTIMAL VALIDITY OF SURROGATE OUTCOMES FOR OVERALL SURVIVAL IN ADVANCED COLORECTAL CANCER.JOURNAL OF CLINICAL EPIDEMIOLOGY. VOL. 68. ISSUE 7. P. 833 -842 25 64% 10
10 BEAUCHEMIN, C , COOPER, D , LAPIERRE, ME , YELLE, L , LACHAINE, J , (2014) PROGRESSION-FREE SURVIVAL AS A POTENTIAL SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER.ONCOTARGETS AND THERAPY. VOL. 7. ISSUE . P. 1101 -1110 17 89% 6

Classes with closest relation at Level 1


Rank Class id link
1 18991 RECIST//RECIST 11//TARGET LESION
2 22170 JOINT MODEL//SHARED PARAMETER MODEL//CONDITIONAL SCORE
3 4137 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//MARGINAL STRUCTURAL MODELS
4 16116 SUBGROUP ANALYSIS//MULTIREGIONAL CLINICAL TRIAL//MULTIREGIONAL TRIAL
5 30357 COMPOSITE ENDPOINTS//WIN RATIO//WORST RANK SCORES
6 36921 WICHITA CLIN TRIALS UNIT//AIRWAY SPLINT//BIOMACROMOLECULE PROTEIN
7 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB
8 12314 COMPETING RISKS//MULTISTATE MODEL//CUMULATIVE INCIDENCE FUNCTION
9 17094 INTERVAL CENSORING//CURRENT STATUS DATA//INTERVAL CENSORED DATA
10 16184 ORPHAN DRUGS//RARE DISEASES//ORPHAN DRUG ACT

Go to start page